← TrialMatch
HomeTrials

Exploration of Differences in Metabolite Concentrations by 7Teslas NMR Spectroscopy in Str

Initially, the exploration of brain metabolism by Nuclear Magnetic Resonance Spectroscopy (MRS) of the high magnetic field proton (1H) (11.7T) applied to acute and chronic animal models of Parkinson's disease (PD) showed glutamatergic hyperactivity within the striatum, one of the components of the basal ganglia. Intere

Condition(s)Parkinson's Disease
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryInitially, the exploration of brain metabolism by Nuclear Magnetic Resonance Spectroscopy (MRS) of the high magnetic field proton (1H) (11.7T) applied to acute and chronic animal models of Parkinson's disease (PD) showed glutamatergic hyperactivity within the striatum, one of the components of the basal ganglia. Interestingly, acute administration of L-dopa and acute, subchronic and chronic deep brain stimulation of the subthalamic nucleus (STN) normalizes these neurochemical profiles. Investigators also show an increase in glutamate levels in the STN ipsilateral to the substantia nigra pars compacta (SNpc) damaged by the neurotoxin, expected phenomenon, but also and surprisingly in the STN controlateral to the lesion. A degeneration of dopaminergic neurons is also observed in the controla
Who can participateInclusion Criteria: Patients will be included: * suffering from idiopathic Parkinson's disease according to UKPDSBB criteria (Gibb \& Lees, 1988; Hughes et al., 1992), * the stage of the disease is I-II according to the Hoehn and Yahr scale, * which do not receive dopaminergic treatment, * duration of disease development 5 years, * without major cognitive impairment (Moca \> 24) * men or women aged 18 to 75, * having understood and signed the informed consent form, * members of a social security scheme. Controls: * subjects male or female aged 18 -75 years * subjects affiliated to a social security scheme. * volunteers who have given their written consent. Exclusion Criteria: Patients will be excluded: * having a severe tremor (\> 3 for a trembling sub-item of UPDRS 3) making the MR examin
Ages18 Years to 75 Years
SexAll
Accepts healthy volunteersYes
Lead sponsorUniversity Hospital, Clermont-Ferrand
LocationsClermont-Ferrand, France; Poitiers, France
Start date2022-04-07
NCT IDNCT04735172
Official listinghttps://clinicaltrials.gov/study/NCT04735172

🔍 Search all trials →